» Articles » PMID: 36959818

Case Report: Cerebrotendinous Xanthomatosis with a Novel Mutation in the Gene Mimicking Behavioral Variant Frontotemporal Dementia

Overview
Journal Front Neurol
Specialty Neurology
Date 2023 Mar 24
PMID 36959818
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cerebrotendinous xanthomatosis (CTX) is a rare autosomal recessive lipid storage disease caused by a mutation in the gene. Due to the disruption of bile acid synthesis leading to cholesterol and cholestanol accumulation, CTX manifests as premature cataracts, chronic diarrhea, and intellectual disability in childhood and adolescence. This report presents a case of CTX with an unusual phenotype of behavioral variant frontotemporal dementia (bvFTD) in middle age.

Case Presentation: A 60-year-old woman presented with behavioral and personality changes. She showed disinhibition, such as hoarding and becoming aggressive over trifles; compulsive behavior, such as closing doors; apathy; and dietary change. The patient showed a progressive cognitive decline and relatively sparing memory and visuospatial function. She had hyperlipidemia but no family history of neurodegenerative disorders. Initial fluid-attenuated inversion recovery (FLAIR) images showed a high signal in the periventricular area, and brain spectroscopy showed hypoperfusion in the frontal and temporal lobes, mimicking bvFTD. However, on physical examination, xanthomas were found on both the dorsum of the hands and the Achilles tendons. Hyperactive deep tendon reflexes in the bilateral biceps, brachioradialis, and knee and positive Chaddock signs on both sides were observed. Four years later, FLAIR images showed symmetrical high signals in the bilateral dentate nuclei of the cerebellum. Her serum cholestanol (12.4 mg/L; normal value ≤6.0) and 7α,12α-dihydroxycholest-4-en-3-one (0.485 nmol/mL; normal value ≤0.100) levels were elevated. A novel likely pathogenic variant (c.1001T>A, p.Met334Lys) and a known pathogenic variant (c.1420C>T, p.Arg474Trp) of the gene were found in trans-location. The patient was diagnosed with CTX and prescribed chenodeoxycholic acid (750 mg/day).

Conclusions: This report discusses the case of a middle-aged CTX patient with an unusual phenotype of bvFTD. A novel likely pathogenic variant (c.1001T>A, p.Met334Lys) was identified in the gene. Early diagnosis is important because supplying chenodeoxycholic acid can prevent CTX progression.

Citing Articles

Semantic variant primary progressive aphasia with ANXA11 p.D40G.

Lee S, Yoon S, Park K, Kim A, Kim H, Jung N Alzheimers Dement. 2025; 21(3):e14566.

PMID: 40042459 PMC: 11881632. DOI: 10.1002/alz.14566.


Polyneuropathy in Cerebrotendinous Xanthomatosis: Diagnostic Challenges and Potential for Therapeutic Intervention.

Camelo-Filho A, Lima P, Cavalcante F, Miyajima O, Santos C, da Rosa R Brain Sci. 2024; 14(11).

PMID: 39595922 PMC: 11591590. DOI: 10.3390/brainsci14111159.


Decoding the Role of CYP450 Enzymes in Metabolism and Disease: A Comprehensive Review.

Abdelmonem B, Abdelaal N, Anwer E, Rashwan A, Hussein M, Ahmed Y Biomedicines. 2024; 12(7).

PMID: 39062040 PMC: 11275228. DOI: 10.3390/biomedicines12071467.


A double CYP27A1 gene mutation in spinal cerebrotendinous xanthomatosis in a patient presenting with spastic gait: a case report.

Min J, Kim Y, Son M, Joo I J Med Case Rep. 2024; 18(1):334.

PMID: 38987800 PMC: 11238493. DOI: 10.1186/s13256-024-04426-1.


Cerebrotendinous xanthomatosis with tremor as the main manifestation: A case report.

Zhao W, Han J, Tao D, Zheng H Medicine (Baltimore). 2024; 103(17):e37976.

PMID: 38669366 PMC: 11049754. DOI: 10.1097/MD.0000000000037976.

References
1.
Fraidakis M . Psychiatric manifestations in cerebrotendinous xanthomatosis. Transl Psychiatry. 2013; 3:e302. PMC: 3784765. DOI: 10.1038/tp.2013.76. View

2.
Kim K, Kubota S, Kuriyama M, Fujiyama J, Bjorkhem I, Eggertsen G . Identification of new mutations in sterol 27-hydroxylase gene in Japanese patients with cerebrotendinous xanthomatosis (CTX). J Lipid Res. 1994; 35(6):1031-9. View

3.
Rystedt E, Olin M, Seyama Y, Buchmann M, Berstad A, Eggertsen G . Cerebrotendinous xanthomatosis: molecular characterization of two Scandinavian sisters. J Intern Med. 2002; 252(3):259-64. DOI: 10.1046/j.1365-2796.2002.01033.x. View

4.
Koyama S, Kawanami T, Tanji H, Arawaka S, Wada M, Saito N . A case of cerebrotendinous xanthomatosis presenting with epilepsy as an initial symptom with a novel V413D mutation in the CYP27A1 gene. Clin Neurol Neurosurg. 2012; 114(7):1021-3. DOI: 10.1016/j.clineuro.2012.01.032. View

5.
Bond K, Brinjikji W, Eckel L, Kallmes D, McDonald R, Carr C . Dentate Update: Imaging Features of Entities That Affect the Dentate Nucleus. AJNR Am J Neuroradiol. 2017; 38(8):1467-1474. PMC: 7960439. DOI: 10.3174/ajnr.A5138. View